Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody

Pediatric Transplantation

Volumn 18, Issue 1, 2014, Pages

  Ghirardo, Giulia ^a   Benetti, Elisa ^a   Poli, Francesca ^b   Vidal, Enrico ^a   Della Vella, Manuela ^a   Cozzi, Emanuele ^a   Murer, Luisa ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

eculizumab; pediatric; plasmapheresis; sensitized transplant recipient

Indexed keywords

CREATININE; ECULIZUMAB; IMMUNOGLOBULIN; METHYLPREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ADOLESCENT; ANTIBODY MEDIATED REJECTION; ARTICLE; BACTERIAL INFECTION; CASE REPORT; CREATININE BLOOD LEVEL; DESENSITIZATION; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PLASMA VOLUME; PLASMAPHERESIS;

ECULIZUMAB; PEDIATRIC; PLASMAPHERESIS; SENSITIZED TRANSPLANT RECIPIENT;

ADOLESCENT; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C5; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, HUMORAL; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; NEPHROTIC SYNDROME; PLASMAPHERESIS; TREATMENT OUTCOME;

EID: 84891825219     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12187     Document Type: Article

References (24)

1. Süsal C, Morath C,. Current approaches to the management of highly sensitized kidney transplant patients. Tissue Antigens 2011: 77: 177-186.
2. Jordan SC, Reinsmoen N, Peng A, et al. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol 2010: 25: 2035-2048.
3. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplant 2000: 70: 887-895.
4. Webber A, Hirose R, Vincenti F,. Novel strategies in immunosuppression: Issues in perspective. Transplant 2011: 91: 1057-1064.
5. Meneghesso D, Reinstadler P, Ghirardo G, et al. Risk of severe bacterial infections after anti-CD20 treatment in paediatric patients with idiopathic nephrotic syndrome and kidney transplant recipients. [Abstract of the 15th Congress of the European Society for Organ Transplantation] Transpl Int 2011: 24 (Suppl 2): 191.
6. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globuline and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplant 2010: 89: 1095-1102.
7. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011: 365: 318-326.
8. Freedman BI, Thacker LR, Heise ER, Adams PL,. HLA-DQ matching in cadaveric renal transplantation. Clin Transplant 1997: 11: 480-484.
9. Iniotaki-Theodoraki AG, Boletis JN, Trigas GCh, Kalogeropoulou HG, Kostakis AG, Stavropoulos-Giokas CG,. Humoral immune reactivity against human leukocyte antigen (HLA)-DQ graft molecules in the early post-transplantation period. Transplant 2003: 75: 1601-1603.
10. Hartono J, Lavingia B, Stastny P, et al. Successful renal re-transplantation in the presence of pre-existing anti-DQ5 antibodies when there was zero mismatch at class I human leukocyte antigen A, B, & C: A case report. J Med Case Rep 2009: 3: 41.
11. Zachary AA, Montgomery RA, Jordan SC, Reinsmoen NL, Claas FH, Reed EF,. 14th International HLA and immunogenetics workshop: Report on understanding antibodies in transplantation. Tissue Antigens 2007: 69: 160-173.
12. Muczynski KA, Cotner T, Anderson SK,. Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium. Kidney Int 2001: 59: 488-497.
13. Roelen DL, Doxiadis IIN, Claas FHJ,. Detection and clinical relevance of donor specific HLA antibodies: A matter of debate. Transpl Int 2012: 25: 604-610.
14. Kranz B, Kelsch R, Kuwertz-Bröking E, Bröcker V, Wolters HH, Konrad M,. Acute antibody-mediated rejection in pediatric renal transplant recipients. Pediatr Nephrol 2011: 26: 1149-1156.
15. Jordan SC, Toyoda M, Vo AA,. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009: 88: 1-6.
16. Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M,. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005: 9: 408-415.
17. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007: 83: 1277-1280.
18. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009: 9: 231-235.
19. Lonze BE, Dagher NN, Simpkins CE, et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010: 10: 2154-2160.
20. Kocak B, Arpali E, Demiralp E, et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: Case reports. Transplant Proc 2013: 45: 1022-1025.
21. Biglarnia AR, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011: 24: e61-e66.
22. Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A,. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation-a case report. Transplant Proc 2011: 43: 2097-2101.
23. Noone D, Al-Matrafi J, Tinckam K, et al. Antibody mediated rejection associated with complement factor H-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012: 12: 2546-2553.
24. Cornell LD, Gloor JD, Nasr SH, et al. Chronic humoral rejection despite C5 inhibition after positive-crossmatch kidney transplantation [abstract]. Am J Transplant 2010: 10 (Suppl 4): 125.